Search - tctmd.com

Displaying 561 - 580 of 619

Sort: Relevancy | Date

News Daily News

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

May 13, 2013

Presentation

Outcomes of Apixaban vs. Warfarin by Type and Duration of A-Fib; Results from the ARISTOTLE Trial

Presenter: Sana M. Al-Khatib

May 06, 2013

News Daily News

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

Yael L. Maxwell

May 03, 2013

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Presentation

Betrixaban vs. Warfarin in A-fib Patients: Results of a Phase 2, Randomized, Dose-Ranging Study

Presenter: Stuart J. Connolly

March 28, 2013

News Daily News

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

March 28, 2013

News Daily News

Remote Postconditioning Reduces AKI in NSTEMI Patients

March 15, 2013

Presentation

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular A-fib

Presenter: Manesh R. Patel

February 03, 2013

News Daily News

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

Caitlin E. Cox

January 30, 2013

Presentation TCT 2012

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Presenter: Paddy Barrett

October 25, 2012

News Daily News

French Registry: Women with STEMI Fare Worse Than Male Counterparts

October 23, 2012

News Daily News

Una Nueva Clase de Anticoagulantes Orales resulta Segura comparada con la Warfarina para Pacientes con FA

October 19, 2012

News Daily News

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

October 19, 2012

Presentation

Efficacy and Safety of the Novel Oral Anticoagulants in A-Fib: A Systematic Review and Meta-Analysis

Presenter: Francesco Dentali

October 18, 2012

News Daily News

Apixaban Matches Bleeding Risk of Aspirin in A-fib Patients

L.A. McKeown

October 10, 2012

Presentation

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Presenter: Greg C. Flaker

October 09, 2012

News Daily News

Apixaban Surpasses Warfarin At All Risk Levels in A-Fib Patients

Caitlin E. Cox

October 04, 2012

Presentation

Efficacy and Safety of Apixaban vs. Warfarin Based on Patient Risk of Stroke and Bleeding in A-fib

Presenter: Renato D. Lopes

October 03, 2012

Advertisement

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

Outcomes of Apixaban vs. Warfarin by Type and Duration of A-Fib; Results from the ARISTOTLE Trial

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

ESC Offers Recommendations on Use of New Oral Anticoagulants

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Betrixaban vs. Warfarin in A-fib Patients: Results of a Phase 2, Randomized, Dose-Ranging Study

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

Remote Postconditioning Reduces AKI in NSTEMI Patients

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular A-fib

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

French Registry: Women with STEMI Fare Worse Than Male Counterparts

Una Nueva Clase de Anticoagulantes Orales resulta Segura comparada con la Warfarina para Pacientes con FA

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

Efficacy and Safety of the Novel Oral Anticoagulants in A-Fib: A Systematic Review and Meta-Analysis

Apixaban Matches Bleeding Risk of Aspirin in A-fib Patients

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Apixaban Surpasses Warfarin At All Risk Levels in A-Fib Patients

Efficacy and Safety of Apixaban vs. Warfarin Based on Patient Risk of Stroke and Bleeding in A-fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content